Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A

Magnus Björkholm1, Caroline E Weibull2, Sandra Eloranta3

  • 1Department of Medicine, Division of Hematology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.

Insights

Older adults over 50 represent a significant portion of Hodgkin lymphoma patients, facing poorer outcomes and underrepresentation in clinical trials. This study highlights their unmet medical needs and advocates for increased trial inclusion.

Area of Science:

  • Oncology
  • Hematology
  • Epidemiology

Background:

  • A substantial proportion (40%) of Hodgkin lymphoma (HL) patients are diagnosed over 50 years old.
  • Older HL patients exhibit significantly worse prognoses compared to younger counterparts.
  • Elderly patients are infrequently enrolled in clinical trials, limiting evidence-based treatment strategies.

Purpose of the Study:

  • To analyze survival outcomes in elderly Hodgkin lymphoma patients.
  • To assess trends in survival and patient characteristics over time.
  • To underscore the need for improved clinical trial access for older adults.

Main Methods:

  • Utilized data from the Swedish Cancer and Lymphoma Registries.
  • Included 7997 Hodgkin lymphoma patients diagnosed between 1973 and 2013.
  • Estimated relative survival ratios (RSRs) stratified by age and sex.

Main Results:

  • Survival rates significantly decrease with advancing age, particularly for those over 70.
  • No substantial improvements in survival were observed for patients aged 45-69 between 2000-2013.
  • Modest survival improvements were noted for patients aged 70 and older during the same period.
  • Patient and disease characteristics remained consistent across the study period.

Conclusions:

  • Elderly Hodgkin lymphoma patients represent a demographic with significant unmet medical needs.
  • Findings support a more proactive strategy for incorporating older patients into clinical trials.
  • This research establishes a crucial baseline for evaluating new therapies, including targeted drugs, in the elderly population.
Abstract

Related Concept Videos

Conservation of Small Populations02:04

Conservation of Small Populations

Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...
17.4K
What is Population Genetics?01:25

What is Population Genetics?

A population is composed of members of the same species that simultaneously live and interact in the same area. When individuals in a population breed, they pass down their genes to their offspring. Many of these genes are polymorphic, meaning that they occur in multiple variants. Such variations of a gene are referred to as alleles. The collective set of all the alleles within a population is known as the gene pool.
64.9K
What are Populations and Communities?00:30

What are Populations and Communities?

Overview
38.0K
Population Growth00:57

Population Growth

Population size is dynamic, increasing with birth rates and immigration, and decreasing with death rates and emigration. In ideal conditions with unlimited resources, populations can increase exponentially, which plots as a J-shaped growth rate curve of population size against time. This type of curve is characteristic of newly-introduced invasive species, or populations that have suffered catastrophic declines and are rebounding.
28.7K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
162